Evidence map›Paper›PMID 38984339›Full record

ArticleWorld journal of psychiatry2024

Fentanyl and xylazine crisis: Crafting coherent strategies for opioid overdose prevention.

Lakshit Jain, Jasleen Kaur, Shahana Ayub, Danya Ansari, Rizwan Ahmed, Abdul Qadir Dada, Saeed Ahmed

Abstract readEditorial
In one paragraph

Article in World journal of psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lakshit JainDepartment of Psychiatry, University of Connecticut, Farmington, CT 06032, United States. lakshit.jain@ct.gov.
Jasleen KaurAddiction Services Division, Connecticut Valley Hospital, Middletown, CT 06457, United States.
Shahana AyubDepartment of Psychiatry, Institute of Living, Hartford, CT 06102, United States.
Danya AnsariDepartment of Medicine, Islamabad Medical and Dental College, Islamabad 44000, Pakistan.
Rizwan AhmedDepartment of Medicine, Liaquat College of Medicine and Dentistry, Karachi 75290, Pakistan.
Abdul Qadir DadaDepartment of Medicine, Trinity School of Medicine, Roswell, GA 30075, United States.
Saeed AhmedAddiction Services and Dual Diagnosis Unit, Saint Francis Hospital and Medical Center, Hartford, CT 06105, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The United States is in the throes of a severe opioid overdose epidemic, primarily fueled by the pervasive use of fentanyl and the emerging threat of xylazine, a veterinary sedative often mixed with fentanyl. The high potency and long duration of fentanyl is compounded by the added risks from xylazine, heightening the lethal danger faced by opioid users. Measures such as enhanced surveillance, public awareness campaigns, and the distribution of fentanyl-xylazine test kits, and naloxone have been undertaken to mitigate this crisis. Fentanyl-related overdose deaths persist despite these efforts, partly due to inconsistent policies across states and resistance towards adopting harm reduction strategies. A multifaceted approach is imperative in effectively combating the opioid overdose epidemic. This approach should include expansion of treatment access, broadening the availability of medications for opioid use disorder, implementation of harm reduction strategies, and enaction of legislative reforms and diminishing stigma associated with opioid use disorder.

Indexed as

BuprenorphineEpidemicFentanylMedications for opioid use disorderOpioid overdoseOpioid use disorderXylazine

Identifiers

PMID38984339
PMCPMC11230091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.